Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Committee stocks on the move: Uber and Vertex Pharma
01:22pm, Tuesday, 04'th Nov 2025
The Investment Committee discuss some of their stocks on the move today.
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
11:46am, Tuesday, 04'th Nov 2025
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
Columbia Balanced Fund Q3 2025 Portfolio Update
02:30am, Tuesday, 04'th Nov 2025
Electronic Arts' shares outperformed the broader market during the period, driven by renewed investor confidence and momentum surrounding several high-profile product announcements. eBay's shares surg
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
11:58pm, Monday, 03'rd Nov 2025
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.8 per share, beating the Zacks Consensus Estimate of $4.55 per share. This compares to earnings of $4.38 per share a year ago.
Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
11:58pm, Monday, 03'rd Nov 2025
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Stre
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript
10:06pm, Monday, 03'rd Nov 2025
Vertex Pharmaceuticals Incorporated ( VRTX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO,
Vertex beats quarterly estimates on cystic fibrosis demand, new drugs
04:20pm, Monday, 03'rd Nov 2025
Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer me
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book
04:12pm, Monday, 03'rd Nov 2025
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.
Vertex Reports Third Quarter 2025 Financial Results
04:02pm, Monday, 03'rd Nov 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 fin
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
02:23pm, Monday, 03'rd Nov 2025
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the first quarter, after the closing bell on Monday, Nov. 3.
2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon
07:37am, Monday, 03'rd Nov 2025
A former pandemic favorite and a lesser-known biopharmaceutical stock both have value to add to a long-term investor's portfolio. Pfizer's growth has slowed from a few years ago, but its tepid stock p
Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years?
07:00am, Monday, 03'rd Nov 2025
Netflix and Vertex benefit from strong pricing power that could come in handy if inflation increases. Both companies are leaders in their niche with excellent growth prospects.
My Top Growth Stock to Buy in November
04:44pm, Sunday, 02'nd Nov 2025
Vertex Pharmaceuticals has three key ways to deliver strong growth. Two factors about the biotech company are especially comforting.
Top Biotech Stocks To Keep An Eye On – October 28th
02:15am, Thursday, 30'th Oct 2025
Danaher, argenex, Recursion Pharmaceuticals, Vertex Pharmaceuticals, and Medpace are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of
Exploring Analyst Estimates for Vertex (VRTX) Q3 Earnings, Beyond Revenue and EPS
10:16am, Wednesday, 29'th Oct 2025
Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for so
